JPWO2021178657A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021178657A5 JPWO2021178657A5 JP2022552573A JP2022552573A JPWO2021178657A5 JP WO2021178657 A5 JPWO2021178657 A5 JP WO2021178657A5 JP 2022552573 A JP2022552573 A JP 2022552573A JP 2022552573 A JP2022552573 A JP 2022552573A JP WO2021178657 A5 JPWO2021178657 A5 JP WO2021178657A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- human
- kit
- administered
- ctla
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062985500P | 2020-03-05 | 2020-03-05 | |
| US62/985,500 | 2020-03-05 | ||
| PCT/US2021/020858 WO2021178657A1 (en) | 2020-03-05 | 2021-03-04 | Methods for treating cancer using a combination of a pd-1 antagonist, a ctla4 antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023515675A JP2023515675A (ja) | 2023-04-13 |
| JPWO2021178657A5 true JPWO2021178657A5 (https=) | 2024-03-11 |
| JP2023515675A5 JP2023515675A5 (https=) | 2024-03-11 |
Family
ID=77614229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022552573A Pending JP2023515675A (ja) | 2020-03-05 | 2021-03-04 | Ｐｄ－１アンタゴニスト、ｃｔｌａ４アンタゴニストおよびレンバチニブまたはその薬学的に許容される塩の組合せを用いる癌を治療する方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20230118596A1 (https=) |
| EP (1) | EP4114464A4 (https=) |
| JP (1) | JP2023515675A (https=) |
| KR (1) | KR20220149740A (https=) |
| CN (1) | CN115443152A (https=) |
| WO (1) | WO2021178657A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023003032A (es) * | 2020-09-15 | 2023-06-01 | Merck Sharp & Dohme Llc | Terapia de combinacion de un antagonista de pd-1 y un antagonista de lag3 y lenvatinib o una sal farmaceuticamente aceptable del mismo para el tratamiento de pacientes con cancer. |
| WO2023160517A1 (zh) * | 2022-02-22 | 2023-08-31 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| WO2024002074A1 (zh) * | 2022-06-28 | 2024-01-04 | 齐鲁制药有限公司 | 包含抗ctla4和抗pd1的混合抗体的药物组合物及其治疗用途 |
| EP4722358A1 (en) * | 2023-06-02 | 2026-04-08 | Ajou University Industry-Academic Cooperation Foundation | Glycerol dehydratase variant and use thereof |
| AU2024311205A1 (en) * | 2023-06-30 | 2026-01-22 | Merck Sharp & Dohme Llc | Treatment method and use of pharmaceutical combination containing conjugate |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160093012A (ko) * | 2013-11-05 | 2016-08-05 | 코그네이트 바이오서비시즈, 인코포레이티드 | 암 치료를 위한 체크포인트 억제제 및 치료제의 배합물 |
| CN105296433B (zh) * | 2014-08-01 | 2018-02-09 | 中山康方生物医药有限公司 | 一种ctla4抗体、其药物组合物及其用途 |
| KR102662228B1 (ko) * | 2015-03-04 | 2024-05-02 | 머크 샤프 앤드 돔 코포레이션 | 암을 치료하기 위한 pd-1 길항제 및 vegfr/fgfr/ret 티로신 키나제 억제제의 조합 |
| TN2017000440A1 (en) * | 2015-04-17 | 2019-04-12 | Bristol Myers Squibb Co | Compositions comprising a combination of an anti-pd-1 antibody and another antibody |
| CN110505882A (zh) * | 2017-03-31 | 2019-11-26 | 默沙东公司 | 用pd-1的拮抗剂和抗ctla4抗体的组合治疗癌症的组合物和方法 |
| SG11201910134SA (en) * | 2017-05-02 | 2019-11-28 | Merck Sharp & Dohme | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof |
| EP3752193A4 (en) * | 2018-02-13 | 2022-02-23 | Merck Sharp & Dohme Corp. | METHODS OF TREATMENT OF CANCER WITH ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES |
| EP3793557A1 (en) * | 2018-05-14 | 2021-03-24 | Merck Sharp & Dohme Corp. | Biomarkers for a combination therapy comprising lenvatinib and a pd-1 antagonist |
| WO2021023117A1 (zh) * | 2019-08-02 | 2021-02-11 | 康方药业有限公司 | 抗ctla4-抗pd-1双特异性抗体及其用途 |
-
2021
- 2021-03-04 EP EP21764706.4A patent/EP4114464A4/en active Pending
- 2021-03-04 KR KR1020227034434A patent/KR20220149740A/ko active Pending
- 2021-03-04 CN CN202180028866.1A patent/CN115443152A/zh active Pending
- 2021-03-04 JP JP2022552573A patent/JP2023515675A/ja active Pending
- 2021-03-04 US US17/801,409 patent/US20230118596A1/en active Pending
- 2021-03-04 WO PCT/US2021/020858 patent/WO2021178657A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2636043C2 (ru) | Анти-vegf/dll4-иммуноглобулины с двойными вариабельными доменами и их применения | |
| JP2018070648A5 (https=) | ||
| JP2021525248A5 (https=) | ||
| FI3796912T3 (fi) | Antiproliferatiivisia yhdisteitä ja bcma:n ja cd3:n vastainen bispesifinen vasta-aine yhdistelmäkäyttöön | |
| JP2021513540A5 (https=) | ||
| JP2021524267A5 (https=) | ||
| JP2019535254A5 (ja) | 抗ｐｄ−ｌ１抗体および変異型 | |
| RU2011103125A (ru) | КОМБИНАЦИЯ АНТАГОНИСТА c-Met И АМИНОГЕТЕРОАРИЛА ДЛЯ ЛЕЧЕНИЯ РАКА | |
| JP2019524714A5 (https=) | ||
| JPWO2019226761A5 (https=) | ||
| TW201536319A (zh) | 抗腫瘤劑及抗腫瘤效果增強劑 | |
| CN117980002A (zh) | 癌症治疗组合 | |
| JP2019516767A (ja) | 癌の治療のためのペンブロリズマブとアベマシクリブとの組合せ | |
| CN119173277A (zh) | 包含sting激动剂的抗体药物缀合物、组合及使用方法 | |
| JPWO2019160755A5 (https=) | ||
| TW202123936A (zh) | 使用包含多重酪胺酸激酶抑制劑和免疫檢查點抑制劑之組合治療癌症 | |
| JPWO2021178657A5 (https=) | ||
| JP2021518348A5 (https=) | ||
| JPWO2021138079A5 (https=) | ||
| CN118697865A (zh) | 治疗淋巴瘤的药物组合 | |
| JP2020507569A5 (https=) | ||
| JPWO2021178779A5 (https=) | ||
| JP2020527594A5 (https=) | ||
| JP6964113B2 (ja) | がんの処置に使用するための５−ブロモ−２，６−ジ−（１ｈ−ピラゾール−１−イル）ピリミジン−４−アミン | |
| WO2026026912A1 (zh) | 抗体药物偶联物和抗vegf抗体的联合应用 |